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lines for medical device therapy were established for hypertrophic cardiomyopathy, but not
for conditions with only anecdotal evidence of arrhythmias, like Fabry cardiomyopathy.
Patients with Fabry cardiomyopathy progressively develop myocardial fibrosis, and sudden
cardiac death occurs regularly. Because 24-hour Holter electrocardiograms (ECGs) might not
detect clinically important arrhythmias, we tested an implanted loop recorder for continuous
heart rhythm surveillance and determined its impact on therapy. This prospective study
included 16 patients (12 men) with advanced Fabry cardiomyopathy, relevant hypertrophy,
and replacement fibrosis in “loco typico.” No patients previously exhibited clinically relevant
arrhythmias on Holter ECGs. Patients received an implantable loop recorder and were pro-
spectively followed with telemedicine for a median of 1.2 years (range 0.3 to 2.0 years). The
primary end point was a clinically meaningful event, which required a therapy change,
captured with the loop recorder. Patients submitted data regularly (14 – 11 times per month).
During follow-up, 21 events were detected (including 4 asystole, i.e., ECG pauses ‡3 seconds)
and 7 bradycardia events; 5 episodes of intermittent atrial fibrillation (>3 minutes) and 5
episodes of ventricular tachycardia (3 sustained and 2 nonsustained). Subsequently, as defined
in the primary end point, 15 events leaded to a change of therapy. These patients required
therapy with a pacemaker or cardioverteredefibrillator implantation and/or anticoagulation
therapy for atrial fibrillation. In conclusion, clinically relevant arrhythmias that require
further device and/or medical therapy are often missed with Holter ECGs in patients with
advanced stage Fabry cardiomyopathy, but they can be detected by telemonitoring
with an implantable loop recorder.  2016 The Authors. Published by Elsevier Inc. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/). (Am J Cardiol 2016;118:264e274)Fabry disease is an X-linked lysosomal storage disorder
that results from a deficiency in alpha-galactosidase A.1 The
cardiac pathogenetic correlate is the accumulation of glo-
botriaosylceramides in cells, which causes left ventricularf Cardiology, Innere Klinik II, Katharinen-Hospital,
Department of Cardiology, Comprehensive Heart Failure
, Germany; cDepartment of Cardiology, II. Medizinische
Straubing GmbH, Straubing, Germany; dMedical Divi-
and Cardiology, Charité, Campus Virchow Klinikum,
and eCatalan Institution for Research and Advanced
t Pompeu Fabra, Barcelona, Spain. Manuscript received
revised manuscript received and accepted April 26, 2016.
nn and Maier contributed equally.
s supported by grants from the Bundesministerium für
chung (BMBF project 01EO1004), by Shire, and by
Germany (research grant for S.K.G. Maier) corporations.
for disclosure information.
g author: Tel: (þ49) 2303-1001832; fax: (þ49) 2303-
s: f.weidemann@katharinen-hospital.de (F. Weidemann).
016 The Authors. Published by Elsevier Inc. This is an open a
-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
0.1016/j.amjcard.2016.04.033(LV) hypertrophy and finally leads to myocardial replace-
ment fibrosis.1e7 In these fibrotic hearts, life-threatening
arrhythmias can develop.8 Thus, patients at risk should be
evaluated regularly for potential arrhythmia treatments. The
current recommendations9 for managing patients with
confirmed Fabry disease include an annual Holter electro-
cardiogram (ECG) assessment to detect different types of
advanced arrhythmias that indicate a potential need to
switch therapy. The Holter ECG covers only a relatively
short period; therefore, it might be beneficial to implement
continuous surveillance for potential arrhythmias in patients
at high risk for severe arrhythmias. Several implantable
devices are available for continuous rhythm surveillance,
such as the Reveal XT device (Medtronic, Minneapolis,
Minnesota). These devices reliably facilitate the detection of
cardiac arrhythmias in routine clinical care.10 However, the
role of these devices in improving the detection of relevant
cardiac arrhythmias that require a change in clinical man-
agement, such as ventricular tachycardia (VT), bradycardia,
and atrial fibrillation (AF), remains to be determined in
patients with Fabry disease. Therefore, the present studyccess article
4.0/).
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Cardiomyopathy/Serious Arrhythmias in Fabry Cardiomyopathy 265aimed to investigate whether an implantable loop recorder
with telemonitoring capabilities could reveal events that
required a change in clinical management in patients at risk
of developing clinically relevant arrhythmias associated
with advanced Fabry cardiomyopathy.
Methods
Study recruitment started in June 2012 and ended in
September 2014. A total of 120 consecutive patients with
Fabry cardiomyopathy were screened in the Fabry centers in
Würzburg and Berlin. Criteria for inclusion were (1)
genetically proved Fabry disease, (2) signs of severe LV
fibrosis (defined in the following section), (3) no previous
detectable clinically relevant arrhythmia (defined in the
following section) on Holter ECG, (4) stable treatment with
enzyme replacement therapy for at least 12 months, and (5)
informed consent for examinations and participation in the
study. All these criteria had to be met for enrollment in the
study. Exclusion criteria were (1) anticoagulation treatment
due to AF, (2) an implanted pacemaker or car-
dioverteredefibrillator (ICD), and (3) signs of AF or VT in
the past.
Severe fibrosis was defined as the presence of at least 2
segments of late enhancement (LE) during cardiac magnetic
resonance imaging (cMRI) or wall motion abnormalities
combined with wall thinning in at least 2 LV segments after
exclusion of coronary artery disease (CAD) with heart
catheterization. In all patients with signs or symptoms of
CAD (i.e., by a stress test), a heart catheterization was
performed to rule out CAD. We defined a clinically relevant
arrhythmia as (1) bradycardia with a heart rate 40 beats/
min during the day, which indicated a need for pacing
therapy; (2) an electrical ventricular pause 3 seconds
during the day, which indicated a need for pacing therapy;
(3) sustained (>30 seconds) or symptomatic nonsustained
(<30 seconds) VT, which indicated a need for an ICD; or
(4) AF that lasted at least 3 minutes, which indicated a need
for anticoagulation.11,12
Of the 120 patients screened, 22 fulfilled the inclusion
criteria, and 6 refused to participate. Consequently, this
prospective study included 16 consecutive patients (4
women) who were considered “at risk” of developing clin-
ically relevant arrhythmias. At baseline, before loop
recorder implantation, an echocardiography, cMRI (when
not contraindicated), Holter ECG, and clinical assessment
were performed in all patients. A yearly follow-up was
conducted with the same assessments performed in the
baseline visit. All patients were asked to transmit data from
the loop recorder by telephone as often as possible. The loop
recorder was explanted when a patient required implantation
of an ICD or pacemaker. According to the Declaration of
Helsinki, we obtained written informed consent for all pa-
tients or their guardians. The local institutional ethics board
approved the study protocol.
We performed LV parasternal long-axis imaging with M-
Mode echocardiography (Vivid 7, GE Vingmed Ultrasound
AS, Horten, Norway) to determine the end-diastolic septal
(interventricular septal wall thickness at end diastole
[IVSd]) and posterior wall thicknesses. In addition, we
measured the left atrial (LA) diameter, and we calculated theLV ejection fraction with Simpson’s formula. We used
blood pool pulsed Doppler of the mitral valve inflow to
quantify the ratio of early-to-late (E/A) diastolic flow ve-
locity and the deceleration time. The transmitral flow was
determined by placing the Doppler window between the tips
of the mitral valve leaflets; we measured the peak flow ve-
locities in early (E wave) and late (A wave) systole. In
addition, tissue Doppler was performed for measuring the
ratio between early transmitral flow and peak early tissue
Doppler velocity (E/E0). Measurements were averaged over
3 cycles.
We performed 2-dimensional speckle tracking with an
EchoPAC (GE Vingmed Ultrasound AS, Horten, Norway)
to acquire standard apical views of the LV for off-line
quantification of myocardial deformation. After manually
selecting the Region of Interest, speckles were applied
automatically and then confirmed by the user. We used
semiautomatic postprocessing to extract the longitudinal
systolic strain of the 17 LV segments.
We performed cMRI to quantify myocardial mass and
cardiac volumes with standard, steady state free precession
cine imaging sequences on a 1.5 T whole body scanner
(Magnetom Avanto, Siemens Medical Systems, Erlangen,
Germany). To detect myocardial fibrosis, we acquired
delayed enhancement images after an intravenous injection
of gadopentetate dimeglumine (0.2 mmol/kg; Magnevist,
Schering AG, Berlin, Germany). We used a T1-weighted
inversion recovery sequence with the breath hold tech-
nique (field of view 240  320 mm2, matrix size 165  256,
slice thickness 8 mm, repetition time 7.5 ms, echo time
3.4 ms, and flip angle 25). Care was taken to use identical
settings in the baseline and follow-up examinations for a
given patient. All consecutive, short-axis slices covering the
whole heart were used to measure the area with pathological
LE. The sum of areas that showed LE was multiplied by the
slice thickness, and then expressed as a percentage of the
LV myocardium volume.
Twelve-lead surface resting ECGs were recorded at a
sweep of 50 mm/s. ECGs were measured manually and
analyzed by a reader who was blinded to the disease stage.
Standard criteria for ECG findings were applied, as follows:
A normal PR interval was defined as 120 to 200 ms. A
normal QRS duration was defined as 70 to 110 ms. LV
hypertrophy was assessed with the SokoloweLyon index,
where the S wave in lead V1 or V2 (whichever was larger)
was added to the R wave in lead V5 or V6 (whichever was
larger), with a minimum cutoff of 3.5 mV. The QT interval
(normal 300 to 440 ms) was measured from the beginning of
the QRS complex to the end of the T wave, which was
defined as the point where the tangent to the downslope of
the T wave intersected the isoelectric line. The corrected QT
duration (normal <440 ms) was calculated with the Bazett’s
formula. For negative or biphasic T waves, the peak was
measured from the nadir of the T wave. ST-segment
elevation was defined as a J point elevation that was
2 mm in the precordial leads and 1 mm in the limb leads.
ST-segment decrease was defined as a J point decrease that
was 1.5 mm in the precordial leads and 1 mm in the limb
leads.
The Holter ECG was started between 8 A.M. and 10 A.M.
and continued for a mean of 22.3 hours. The data were
Table 1
Baseline characteristics of all Fabry patients
Patient
number
Genetics Age
(years)
Sex Height
(cm)
Weight
(kg)
Gal-A activation
(nmol/min/mg)
lysoGb3
(ng/ml)
ERT for
(years)
Kidney
TX
Dialysis GFR (MDRD)
(ml/min/1.73 m2)
TIA/Stroke* Dyshidrosis Angiokeratoma
1 Exon7. Mutation E341 K 53 M 185 57 0.03 63.1 10 0 0 83 þ þ þ
2 Exon 7. Del c.1221 delA 58 F 163 56 0.14 18.7 3 0 0 55 0 0 0
3 Exon3. Mutation D136 E 70 F 165 71 0.15 11.2 10 0 0 76 0 0 0
4 Intron 3. IVS3þ1 G > A 45 M 184 75 0.04 21.2 12 þ 0 47 0 þ 0
5 Exon 7. Mutation E341 K 49 M 180 72 0.02 65.7 11 0 0 110 0 þ 0
6 Exon7. Mutation c.1208.del 45 M 184 84 0.02 15.0 11 þ þ 58 0 þ þ
7 Exon 7. Deletion 354 fs Del 15 bp 54 F 165 64 0.19 10.1 9 0 0 82 0 þ þ
8 Transition c664A > G;
Mutation N215S
67 M 170 63 0.13 6.0 2 0 0 103 0 þ þ
9 Exon 1. c.162 del T 54 M 177 78 0.08 30.6 13 þ 0 40 þ þ þ
10 Exon 7. Mutation c.1208 del 49 M 178 72 0.03 28.1 12 0 0 85 0 þ 0
11 Exon 1. C134T > C [L45P] 36 M 193 83 0 63.4 3 0 0 100 þ þ 0
12 Exon 3. Mutation D136 E 48 M 182 83 0.02 15.1 11 þ 0 74 0 þ 0
13 Intron 6 Trans IVS6-10G
> A Splice-Site-Mutation
Mut c.1000-10G > A
36 M 187 86 0.04 30.3 2 0 0 80 0 0 þ
14 Exon 6. c. 973 G > A
Mutation G325S
73 F 156 52 0.23 7.2 3 0 0 39 0 0 0
15 c.747A > G 56 M 170 60 0.03 74.7 2 0 0 102 0 0 þ
16 c.982 G > C 43 M 148 68 0.02 114 4 0 0 116 0 0 þ
ERT ¼ enzyme replacement therapy; F ¼ female; GFR ¼ glomerula filtration rate; M ¼ male; TIA ¼ transistoric ischemic attack; TX ¼ transplantation.
* All TIA and stroke were not due to documented atrial fibrillation.
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Cardiomyopathy/Serious Arrhythmias in Fabry Cardiomyopathy 267analyzed by a reader blinded to the disease stage. Premature
ventricular beats (PVBs) were counted automatically, with
manual correction. All counts were then corrected to a
fictive duration of exactly 24 hours. PVB were classified as
ventricular or supraventricular in origin, and they were
ranked as a singlet, couplet, triplet, or run. A run was
defined as more than 3 PVBs in a row.
All patients received identical loop recorders with tele-
medicine capabilities (Reveal XT; Medtronic). Immediately
before the surgical procedure, patients were screened for an
eligible implant position in the body with the vendor-supplied
dermal ECG vector measurement tool. All patients showed
good signal quality at the parasternal left position. After aseptic
preparation and local anesthesia, an incision approximately
3 cm long was made parasternal left. Then, a subfascial pouch
8 to 10 cm long in the caudal direction was prepared with blunt
dissection. The Reveal device was inserted and fixed by
muscular ligationwithMersilene. The incisionwas closedwith
Vicryl subcutan and Prolene intracutan. Then, the device was
interrogated and activated with the external programmer.
Directly after the implantation procedure, the settings were
programmed according to the study specifications (fast ven-
tricular tachycardia: detection: on; ECG recording: on; inter-
val: 290 ms, 30/40 beats; VT: detection: on; ECG recording:
on; interval: 370 ms, 16 beats; asystole: detection: on; ECG
recording: on; bradycardia: detection: on; ECG recording: on;
interval: 1,500 ms, 4 beats; symptoms: detection: on; ECG
recording: 3 episodes e 7.5 minutes; atrial tachycardia/AF:
detection: on; ECG recording: on - all episodes). All patients
received a corresponding transmitter. We requested that they
should transfer data daily, whenever possible. Transmitted data
were interrogated at the study center daily (on workdays)
through an electronic internet platform.
Continuous data are presented as the mean (SD); cate-
gorical variables are presented as numbers (percentages).
Categorical data were compared across groups with the chi-
square test. A 2-tailed probability value <0.05 was
considered significant. Statistical analysis was performed
with IBM SPSS, version 22 for Windows (SPSS, IBM,
Chicago, Illinois).
Results
Table 1 lists the genetic and clinical data for every in-
dividual patient and information about their typical Fabry
organ involvement. Fifteen patients had a classical mutation,
and one patient had a late-onset mutation, which typically
presents as a cardiac variant. Most patients were men (75%),
and all had markedly elevated levels of globotriaosyl-
sphingosine (Lyso-Gb3; mean 36.3  32 ng/ml). The mean
age was 52  11 years, and all were on enzyme replacement
therapy for at least 2 years. All patients submitted the data
regularly, at a rate of 14  11 times per month. After device
implantation, patients were prospectively followed with
telemedicine for a median of 1.2 years (range 0.3 to
2.0 years), and no patient died during follow-up.
In Table 2, all individual echocardiographic and cMRI
data are shown with the average values. All patients showed
LV hypertrophy (IVSd 11 mm), and all but one had
visible papillary muscle thickening. One patient had a
reduced ejection fraction. Seven patients had an E/E0 above15, which suggested elevated diastolic filling pressure. The
global systolic strain averaged 13  5%, and systolic
strain in the basal lateral wall was markedly reduced
to 96%, a sign of both reduced regional LV function and
replacement fibrosis in loco typico.
Three patients did not receive cMRIs, due to claustro-
phobia; one was not eligible due to terminal renal insuffi-
ciency/dialysis. All patients with cMRIs (n ¼ 12) showed
replacement fibrosis in loco typico. All patients who did not
receive cMRIs had visible and quantifiable thinning of the
posterior wall (defined as LV posterior wall thickness at end
diastole 2 mm thinner than the IVSd). Figure 1 shows
representative examples of echocardiography and cMRI.
Table 3 lists the results from the ECGs at rest. Only 2
patients had a prolonged QTc interval. Seven patients had a
positive LV Sokolov index for LV hypertrophy, and 11
patients had T negativities in V5 and V6. Figure 1 shows a
typical ECG at rest.
All patients were in sinus rhythm for both the resting and
Holter ECG recordings. During the Holter ECG, the mean
heart rate was 68  10 during the day and 57  6 during the
night. No relevant bradycardia or VT was detected. Three
patients had ventricular runs for <10 beats. Eight patients
had supraventricular runs with maximums of <25 beats.
Table 4 lists all the clinically relevant events recorded.
Three male patients had a documented asystole that
prompted a recommendation for pacing therapy. One patient
experienced syncope, one experienced dizziness, and the
third patient had no noticeable symptoms. Because these 3
patients had also at least one VT documented with the event
recorder, the final recommendation was an ICD implant,
which had an implemented pacing function. One female
patient experienced 6 events of asystole, and the longest
electrical ventricular pause lasted 3.4 seconds. Because she
was completely asymptomatic, she was not scheduled for a
device implantation; instead, she received a careful watch
and wait regime. Figure 2 shows typical recordings for 2
patients with asystole.
One male patient experienced several episodes of
symptomatic bradycardia; thus, pacemaker implantation
was recommended. One male patient experienced brady-
cardia of 26 beats/min, and he experienced syncope.
Because this patient had severe cardiac hypertrophy and a
large area of fibrosis (3.21% of the LV), a prophylactic ICD
was recommended. In another male patient who had been
taking a b blocker, we detected one asymptomatic brady-
cardia of 27 beats/min. The recommendation for this patient
was termination of beta-blocker therapy. In addition, 4 pa-
tients (1 woman and 3 men) had several documented epi-
sodes of asymptomatic bradycardia. Based on these events,
a careful watch and wait regime was recommended. How-
ever, later, 3 of these patients (all men) had a documented
VT; thus, an ICD was recommended. Figure 2 shows
typical intracardiac electrograms (IEGMs) from 2 patients
with bradycardia.
In 3 male and 2 female patients, the loop recorder
documented intermittent asymptomatic AF that lasted at
least 3 minutes. Because all 5 patients had hypertrophic
cardiomyopathy, therapeutic anticoagulation was recom-
mended. Figure 3 shows typical IEGM data from 2 patients
with intermittent AF.
Table 2
Organ specific values
Patient
number
Echocardiography Magnetic Resonance Imaging
LVDd
(mm)
LVDs
(mm)
IVSd
(mm)
LVPWd
(mm)
EF
(%)
LA
(mm)
DT
(ms)
E/E0 AO root
(mm)
LV
hypertrophy
Thick papillary
muscle
Posterior wall
thinning
LVMI
(g/m2)
LVED
Vol. (ml)
LVES
Vol. (ml)
Stroke
Vol. (ml)
Cardiac
output (l/min)
Fibrosis (%)
1 45 27 12 12 59 38 283 15 39 þ þ 0 146 152 37 115 6.9 1.23
2 39 20 18 16 63 41 160 12 32 þ þ 0 205 115 34 81 4.6 1.21
3 46 35 11 7 61 37 228 19 35 þ þ þ NA NA NA NA NA NA
4 54 36 12 13 55 36 197 12 43 þ þ 0 127 179 77 102 5.9 2.14
5 45 29 11 11 73 36 224 13 37 þ þ 0 77 135 35 100 6.6 0.74
6 60 31 11 10 76 41 187 11 33 þ þ 0 109 198 36 162 9 1.12
7 47 28 12 10 54 40 195 18 32 þ þ 0 117 130 39 91 5.6 2.8
8 55 42 13 7 59 42 181 10 42 þ þ þ NA NA NA NA NA NA
9 51 24 13 13 55 36 275 14 35 þ þ 0 131 117 36 81 6.1 4.27
10 39 24 13 11 68 37 301 14 34 þ þ þ NA NA NA NA NA NA
11 64 50 11 11 51 40 135 12 41 þ 0 0 107 263 140 123 6.6 0.65
12 50 32 12 9 71 38 352 20 39 þ þ þ 111 180 58 122 6.3 3.92
13 42 27 12 13 67 28 268 10 32 þ þ 0 85 156 53 103 7.7 1.03
14 47 23 14 13 70 41 181 16 28 þ þ 0 133 110 26 84 5.9 1.86
15 37 23 20 15 60 38 208 16 31 þ þ þ NA NA NA NA NA NA
16 39 25 17 18 63 36 256 19 34 þ þ 0 183 107 33 70 4.8 3.21
Mean 48 8 30 8 13 3 12 3 63 7 38 3 233 58 14 3 35 4 þ¼16 (100%) þ¼15 (64%) þ¼5 (31%) 124 36 149 44 49 30 101 24 6.5 1.2 1.86 1.33
AO ¼ aortic; DT ¼ deceleration time; EF ¼ ejection fraction; LV ¼ left ventricular; LVDd ¼ left ventricular diastolic diameter; LVED ¼ left ventricular end-diastolic; LVES ¼ left ventricular end-systolic;
LVMI ¼ left ventricular mass index; LVSd ¼ left ventricular systolic diameter; LVPWd ¼ left ventricular posterior wall thickness at diastole; IVSd ¼ interventricular septal wall thickness at diastole; NA ¼ not
available.
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Figure 1. Example of a 45-year-old male patient with typical, advanced Fabry cardiomyopathy. In this patient, bradycardia, asystole, intermittent AF, and
sustained VT were detected with an implanted loop recorder. Left (A): representative echocardiography from a parasternal long-axis viewpoint shows eccentric
hypertrophic cardiomyopathy. Right top (B): representative cardiac magnetic resonance image in the short-axis orientation. The red arrow indicates a large area
with positive LE, which indicates replacement fibrosis. Right bottom (C): 12-lead, resting electrocardiograph with signs of LV hypertrophy in advanced Fabry
cardiomyopathy. EF ¼ ejection fraction; hs-TNT ¼ highly sensitive troponin; LV ¼ left ventricle; LVPWd ¼ left ventricular posterior wall thickness at end
diastole; NT-proBNP ¼ N-terminal propeptid of the brain natriuretic peptide.
Table 3
Electrocardiography
Patient number Heart
rhythm
Heart axis Heart rate
(min1)
P- dur.
time (ms)
PQ dur. (ms) QRS dur. (ms) QTc dur. (ms) Sokolow
index (þ/0)
T-wave
negativity (þ/0)
ST elevation
(þ/0)
1 SR Vertical 56 100 120 130 425 þ þ 0
2 SR Intermediate 54 80 100 100 588 þ þ 0
3 SR Intermediate 68 80 120 80 383 0 þ 0
4 SR Intermediate 64 100 150 100 427 þ 0 0
5 SR Intermediate 64 100 120 100 392 0 0 0
6 SR Intermediate 52 100 140 90 400 þ 0 0
7 SR Intermediate 50 110 140 120 420 þ þ 0
8 SR Left 52 80 160 130 437 0 þ 0
9 SR Intermediate 91 90 110 100 394 þ þ 0
10 SR Intermediate 78 80 80 100 388 0 0 0
11 SR Intermediate 52 110 180 120 382 þ 0 0
12 SR Left 72 100 110 110 427 0 þ 0
13 SR Left 54 100 110 100 379 0 þ 0
14 SR Left 58 100 160 160 492 0 þ 0
15 SR Intermediate 64 90 150 110 434 0 þ 0
16 SR Intermediate 80 80 130 100 439 0 þ 0
Mean 6312 9511 13026 10919 42653 þ¼7(44%) þ¼11(67%) þ¼0 (0%)
Dur ¼ duration; SR ¼ sinus rhythm.
Cardiomyopathy/Serious Arrhythmias in Fabry Cardiomyopathy 269VTs were documented in 4 male patients. Of these, 3 had
sustained VTs, with syncope in one, chest pain in another,
and no symptoms in the third; accordingly, ICDs wererecommended. The fourth patient had 2 nonsustained
asymptomatic VTs, and the longer episode lasted 16 sec-
onds at a heart rate of 200 beats/min. This patient also
Table 4
Events detected by implantable loop recorder separated for clinical relevance (¼ changing therapy, n ¼ 15) and irrelevance (¼ watch and wait, n ¼ 6)
Event: Asystole
Patient number Numbers Type of Event Max. duration (sec) Time Recommendation
6 4x Asystole 3.7 6-9 am ICD-Implantation*
4 3x Asystole 3.3 10 pm-9am ICD-Implantation*
1 53x Asystole 4.4 10 pm-12 am ICD-Implantation*
2 6x Asystole 3.3 10 pm-6am Watch and wait
Event: Bradycardia
Patient number Numbers Event Min. frequency (1/min) Time Recommendation
5 19x Bradycardia 39 10 pm-12 am Pacemaker-Implantation
9 1x Bradycardia 27 6-9 am Termination of b-Blockers
16 1x Bradycardia 26 9-12 am ICD-Implantation†
3 1x Bradycardia 54 10 pm-6 am Watch and wait
4 >1700x Bradycardia 37 10 pm-9 am Watch and wait
6 >1400x Bradycardia 38 9 pm-12 am Watch and wait
8 >5000x Bradycardia 36 10 pm-9 am Watch and wait
Event: Atrial Fibrillation
Patient number Event Max. frequency (1/min) Max. time (sec) Recommendation
1 Intermittent AF 46 >85000 Anticoagulation
3 Intermittent AF 105 7200 Anticoagulation
6 Intermittent AF 103 1560 Anticoagulation
4 Intermittent AF 120 240 Anticoagulation
7 Intermittent AF 122 1560 Anticoagulation
Event: Ventricular Tachycardia
Patient number Numbers Event Max. frequency (1/min) Max. time (sec) Recommendation
1 3x VT 188 48 ICD-Implantation
4 5x VT 200 360 ICD-Implantation
6 2x VT 200 16 ICD-Implantation
8 3x VT 206 45 ICD-Implantation
3 1x VT 200 4 Watch and wait
AF ¼ atrial fibrillation; ICD ¼ implantable cardioverteredefibrillator; VT ¼ ventricular tachycardia.
* Because of additional ventricular tachycardia.
† Because of large area of fibrosis.
270 The American Journal of Cardiology (www.ajconline.org)presented with episodes of bradycardia, which suggested a
pacing indication. Therefore, the final decision was to
implant an ICD. In addition, one female patient had an
asymptomatic nonsustained VT, which lasted 4 seconds. In
this patient, a careful watch and wait regime was recom-
mended. Figure 3 shows typical IEGM examples from 2
patients with VTs.
When comparing clinically relevant events and the
evaluated general and cardiomyopathy parameters, no sig-
nificant correlation for any parameter was detected in these
patients who were by the definition of inclusion criteria
advanced cardiomyopathies.
Discussion
It is well established that patients with Fabry disease can
develop clinically relevant arrhythmias; in addition, most
die due to cardiac complications.8,13 However, no previous
study has systematically investigated both the frequency and
the kind of arrhythmias in patients at risk. The presentprospective study focused on detecting relevant arrhythmias
that could change clinical management in patients with
advanced Fabry cardiomyopathy. Our main findings were:
(1) modern technology has made it feasible to provide
permanent telemonitoring for all types of arrhythmias; (2) a
high number of clinically relevant arrhythmias were detec-
ted over time in Fabry hearts with advanced replacement
fibrosis, despite negative results from an initial Holter ECG;
(3) we found both supraventricular and ventricular ar-
rhythmias; consequently, a specific treatment was necessary
in most patients to prevent stroke, syncope, and sudden
cardiac death.
Advanced Fabry cardiomyopathy is characterized by LV
hypertrophy and replacement fibrosis in the basal postero-
lateral wall.2,6,7,14e16 The present study focused on patients
with Fabry disease that showed either a direct sign of
replacement fibrosis (2 LE positive segments) or an indirect
sign of severe fibrosis (regional wall motion abnormalities
in the posterolateral wall). The presence of fibrosis was the
main inclusion criterion, because a recent study showed a
Figure 2. Examples of arrhythmias detected in patients with Fabry who received an implanted loop recorder. ECGs show: (A) 2 patients with asystole and (B) 2
patients with bradycardia. EF ¼ ejection fraction; HR ¼ heart rate; hs-TNT ¼ highly sensitive troponin; LV ¼ left ventricle; LVPWd ¼ left ventricular
posterior wall thickness at end diastole; NT-proBNP ¼ N-terminal propeptid of the brain natriuretic peptide.
Cardiomyopathy/Serious Arrhythmias in Fabry Cardiomyopathy 271close correlation between the burden of fibrosis and ma-
lignant arrhythmias in patients with Fabry cardiomyopathy.9
In these patients, considered at risk, careful monitoring is
desirable. An implantable loop recorder, such as the
Reveal XT device, is an expedient tool for permanenttelemonitoring.10 By transmitting all detected arrhythmias
through telephone to the Fabry center, it was possible to
securely diagnose, and subsequently, treat all relevant
arrhythmias. The loop recorder detected different types of
supraventricular arrhythmias, including AF, bradycardia,
Figure 3. Examples of arrhythmias detected in patients with Fabry who received an implanted loop recorder. ECGs show: (A) 2 patients with intermittent AF
and (B) 2 patients with VT. EF ¼ ejection fraction; HR ¼ heart rate; hs-TNT ¼ highly sensitive troponin; LV ¼ left ventricle; LVPWd ¼ left ventricular
posterior wall thickness at end diastole; NT-proBNP ¼ N-terminal propeptid of the brain natriuretic peptide.
272 The American Journal of Cardiology (www.ajconline.org)and sinus arrest. Although all patients had sinus rhythm at
baseline (an inclusion criterion), the E/E0 was above 10 in all
patients, which suggested elevated LA pressure. In addition,
LA size was increased in a lot of patients. Consistent with
clinical experience, it was not surprising to find that a
dilated LA with increased pressure was vulnerable tosupraventricular arrhythmias. These morphologic and elec-
trical LA abnormalities are typical for advanced hypertro-
phic cardiomyopathy in patients with general and Fabry
cardiomyopathies.13,17e19
More dangerous than atrial arrhythmias, we frequently
detected ventricular arrhythmias, such as nonsustained and
Cardiomyopathy/Serious Arrhythmias in Fabry Cardiomyopathy 273sustained VTs, in patients considered at risk. Interestingly,
none of the patients with a documented VT exhibited pro-
longed QT intervals on the ECG at rest. Although all these
patients with VT had myocardial fibrosis, based on the in-
clusion criteria, they did not have the largest volumes of
fibrosis. Thus, neither the ECG at rest nor the total quantities
of fibrosis were good predictors for the VTs later docu-
mented. When asked, only 1 patient reported that he expe-
rienced syncope during the VT. Thus, it seemed clear that
many potentially life-threatening arrhythmias are not
recognized by patients with progressive Fabry disease. The
exact origin of these VTs remains an open question. Recent
studies in ischemic and dilated cardiomyopathy have shown
that the presence of midventricular LE/fibrosis was closely
associated with the development of VTs. That finding sug-
gested that these tachycardias are often generated at the
border zone of myocardial fibrosis or a scar.20e22 Thus, it
can be speculated that the VTs may originate at the basal
posterolateral wall, where cMRI data indicated that all pa-
tients had replacement fibrosis; consequently, progressive
fibrosis visualized with MRI may be an indicator of
generalized electrical instability of the heart. In this study,
all patients with a sustained VT received an implanted ICD
for primary prophylaxis of sudden cardiac death.
Current guidelines for managing patients with Fabry
recommend an annual Holter ECG.9 However, our results
suggested that the Holter ECG might not be sufficient for
patients at risk. Instead, in patients with severe Fabry car-
diomyopathy, continuous surveillance with an implanted
loop recorder and telemonitoring should be preferred.
Stroke is also a very common clinical event in patients
with early and advanced Fabry.23,24 Our data confirmed that
many patients with advanced cardiomyopathy develop
intermittent AF, which may explain the potential for
thromboembolic stroke. Thus, in patients at risk, a thorough
search for AF should be performed, and in case of a positive
finding, therapeutic anticoagulation should be discussed.
The worst clinical event in Fabry disease is sudden car-
diac death, which has been described as a major factor in the
diminished life expectancy of these patients.9,25 The present
study confirmed previous studies,8,13 which showed that
patients with advanced cardiomyopathy frequently develop
VT. Based on other forms of hypertrophic cardiomyopathy,
it is well known that rhythm events, such as VT and ven-
tricular fibrillation, are primarily responsible for sudden
cardiac death.17 This suggests that, whenever a sustained
VT is documented in a patient with Fabry, an ICD should be
discussed. Further studies must determine whether this
intervention will effectively prolong life expectancy in these
patients.
This prospective study focused on detecting clinically
relevant arrhythmias. Thus, we did not primarily aim to
investigate advanced pharmaceutical and device-related
therapy for arrhythmias in patients with Fabry.
Although 120 Fabry patients were screened, the total
number of patients included in the present study was rela-
tively low. This was because we only included patients with
very advanced Fabry cardiomyopathy. Because large
numbers of events were detected in most of the selected
patients, despite negative initial 12-channel and Holter
ECGs, we speculated that the inclusion criteria may havebeen too strict. In this context, it is very interesting that in
these advanced cardiomyopathy hearts, no significant cor-
relation for any parameter with the events was detected,
even not for the gender. Thus, further studies should use an
implanted loop recorder to focus on the earlier stages of
Fabry cardiomyopathy.Disclosures
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